Literature DB >> 7695917

Polarity of secretion of alpha 1-antitrypsin by human respiratory epithelial cells after adenoviral transfer of a human alpha 1-antitrypsin cDNA.

W Siegfried1, M Rosenfeld, L Stier, L Stratford-Perricaudet, M Perricaudet, A Pavirani, J P Lecocq, R G Crystal.   

Abstract

alpha 1-Antitrypsin (alpha AT) deficiency, a hereditary cause of progressive emphysema, can potentially be treated by transfer of a functional human alpha 1AT gene to the respiratory epithelium. For such an approach to be successful, alpha 1AT must be provided to both the interstitium and the epithelial surface--that is, the alpha 1AT directed by the transferred gene must be secreted to both the apical and basolateral surfaces of the epithelial cells. To evaluate this concept, a recombinant, replication-deficient adenoviral vector (Ad-alpha 1AT) containing a human alpha 1AT cDNA driven by an adenovirus major late promoter was used to infect Bet-1A human respiratory epithelial cells. The infected cells expressed Ad-alpha 1AT-directed mRNA transcripts and synthesized and secreted functional human alpha 1AT as shown by [35S]methionine labeling and immunoprecipitation of a 52-kD glycosylated human alpha 1AT molecule capable of interacting with neutrophil elastase, its natural substrate. Bet-1A cells grown on microporous polycarbonate membranes formed tight junctions (resistance > 150 omega x cm2). After infection with Ad-alpha 1AT, [35S]methionine labeling and enzyme-linked immunoassay demonstrated that alpha 1AT was secreted into both the apical and basolateral compartments, with an average apical to basolateral ratio of 1.9 +/- 0.2. Thus, human respiratory epithelial cells infected with a recombinant adenoviral vector containing a human alpha 1AT cDNA secrete alpha 1AT across both the apical and basolateral cell membranes, suggesting that the respiratory epithelium could serve as a target for in vivo gene therapy of alpha 1AT deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695917     DOI: 10.1165/ajrcmb.12.4.7695917

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  6 in total

1.  The lung as a metabolic factory for gene therapy.

Authors:  John F Engelhardt
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  In vivo secretion of the mouse immunoglobulin G Fc fragment from rat submandibular glands.

Authors:  Gabor Z Racz; Paola Perez-Riveros; Janik Adriaansen; Changyu Zheng; Bruce J Baum
Journal:  J Gene Med       Date:  2009-07       Impact factor: 4.565

Review 3.  Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants.

Authors:  Megan Meyer; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

Review 4.  Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.

Authors:  Maria J Chiuchiolo; Ronald G Crystal
Journal:  Ann Am Thorac Soc       Date:  2016-08

5.  5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency.

Authors:  Christian Mueller; Gwladys Gernoux; Alisha M Gruntman; Florie Borel; Emer P Reeves; Roberto Calcedo; Farshid N Rouhani; Anthony Yachnis; Margaret Humphries; Martha Campbell-Thompson; Louis Messina; Jeffrey D Chulay; Bruce Trapnell; James M Wilson; Noel G McElvaney; Terence R Flotte
Journal:  Mol Ther       Date:  2017-04-10       Impact factor: 11.454

6.  Widespread airway distribution and short-term phenotypic correction of cystic fibrosis pigs following aerosol delivery of piggyBac/adenovirus.

Authors:  Ashley L Cooney; Brajesh K Singh; Laura Marquez Loza; Ian M Thornell; Camilla E Hippee; Linda S Powers; Lynda S Ostedgaard; David K Meyerholz; Chris Wohlford-Lenane; David A Stoltz; Paul B McCray; Patrick L Sinn
Journal:  Nucleic Acids Res       Date:  2018-10-12       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.